uniQure Defies 71.07% Volume Drop with 10.84% Surge Ranks 119th in Market Movers Amid Gene Therapy Hype

On September 25, 2025, uniQure (QURE) surged 10.84% despite a 71.07% drop in trading volume to $0.87 billion, ranking 119th among market movers. The biotech firm’s shares traded at elevated levels amid investor speculation surrounding its gene therapy pipeline, though no material corporate updates were disclosed in the reporting period.

Market participants noted limited catalysts for the price action, as regulatory filings and clinical trial timelines remained unchanged from prior quarters. Analysts attributed the volatility to broader sector rotation rather than company-specific news, with gene therapy stocks experiencing uneven performance across the biotech index. Short-term momentum appears disconnected from fundamental metrics, suggesting algorithmic trading activity may have influenced the session’s dynamics.

To run this back-test accurately I need to clarify a few implementation details: 1. Equity universe • Should I draw the 500 stocks from the entire U.S. exchange-listed universe (NYSE + NASDAQ + AMEX), or from a specific index such as the Russell 3000 or S&P 500? 2. Rebalancing convention • On each trading day we would rank stocks by that day’s trading volume, buy the top 500 at the close, and liquidate them at the next day’s close (i.e. a one-day holding period). • Is that the convention you want, or do you prefer buy at next day’s open instead? 3. Weighting & capital allocation • Equal-weight each position (1/500 of capital) or volume-weighted / market-cap-weighted? • Assume full reinvestment of capital each day, with no cash drag? 4. Transaction costs • Should we include a bid-ask or commission assumption (e.g., 2 bps per entry and exit), or ignore costs? 5. Benchmark (optional) • Any benchmark you’d like to compare against (e.g., SPY)? Once I have these details I can set up the data-gathering plan and run the back-test.